XENE Earnings Date: Nov 2, 2026 (Estimated) — Xenon Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is XENE's next earnings date?
Xenon Pharmaceuticals Inc. (XENE) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.13 on revenue of $1.3M.
How did XENE do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Xenon Pharmaceuticals Inc. posted EPS of -$1.11 versus the -$1.14 estimate, a beat of 4.3%. Revenue was $0 against a $1.7M estimate. The stock's 1-day post-earnings move was -1.8%.
How much does XENE stock move after earnings?
XENE beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.0% (up or down) in the day after earnings.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.14 | -1.11 | +4.31% | $0 | ✅ Beat | -1.84% | -0.50% | -7.44% |
| 2026-05-07 | Q1 2026 | -1.19 | -1.17 | +1.68% | $0 | ✅ Beat | +0.79% | +0.00% | -8.55% |
| 2026-02-26 | Q4 2025 | -1.20 | -1.31 | -9.17% | $0 | ❌ Miss | -3.76% | -6.39% | +21.28% |
| 2025-11-03 | Q3 2025 | -1.16 | -1.15 | +0.86% | $0 | ✅ Beat | -4.94% | -6.59% | +7.71% |
| 2025-08-11 | Q2 2025 | -1.00 | -1.07 | -7.00% | $0 | ❌ Miss | +5.51% | +10.88% | +8.80% |
| 2025-02-27 | Q4 2024 | -0.84 | -0.84 | +0.00% | $0 | ➖ Inline | -3.37% | -2.69% | -10.57% |
| 2024-11-12 | Q3 2024 | -0.81 | -0.81 | +0.00% | $0 | ➖ Inline | -3.27% | -10.46% | -9.08% |
| 2024-02-29 | Q4 2023 | -0.76 | -0.64 | +15.79% | $0 | ✅ Beat | -0.76% | -2.20% | -10.72% |
Showing last 8 quarters.